NCT05797701View on ClinicalTrials.gov

A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 28, 2021

Primary Completion Date

September 6, 2021

Study Completion Date

September 6, 2021

Conditions
Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Interventions
DRUG

SAR443820

Tablet by oral administration

DRUG

SAR443820

Capsule by oral administration

Trial Locations (1)

55144

Prism Research-Site Number:8400001, Saint Paul

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT05797701 - A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2) | Biotech Hunter | Biotech Hunter